Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion type Assertion NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_head.
- NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion description "[CCL5 could be considered as a biomarker for disease progression in stage II breast cancer patients, with the CCL5(+)/ER-alpha(-) combination providing improved prediction of disease progression, primarily in the stage IIA subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_provenance.
- NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion evidence source_evidence_literature NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_provenance.
- NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion SIO_000772 16899591 NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_provenance.
- NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion wasDerivedFrom befree-20140225 NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_provenance.
- NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_assertion wasGeneratedBy ECO_0000203 NP744931.RAp15AdEbiySibKbV96ci-XhS0Qk7DZ-HoB8HDzKz9P9E130_provenance.